Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease

Atherosclerosis

Volumn 156, Issue 1, 2001, Pages 217-225

  Asztalos, Bela F ^a   Brousseau, Margaret E ^a   McNamara, Judith R ^a   Horvath, Katalin V ^a   Roheim, Paul S ^b   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Apolipoproteins; Cholesterol; HDL; Lipoproteins; Tangier disease

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CATABOLISM; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MALE; MORBIDITY; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RELATIVE; TANGIER DISEASE;

ADULT; AGED; APOLIPOPROTEINS; CORONARY DISEASE; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PARTICLE SIZE; RISK FACTORS; SEX CHARACTERISTICS; TANGIER DISEASE;

EID: 0035024968     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00643-2     Document Type: Article

References (39)

1. Fredrickson D.S., Altrocchi P.H., Avioli L.C., Goodman D.S., Goodman H.C. Tangier disease: combined clinical staff conference at the National Institute of Health. Ann. Intern. Med. 55:1961;1016.
2. Fredrickson D.S. The inheritance of high density lipoprotein deficiency (Tangier disease). J. Clin. Invest. 43:1964;228.
3. Schaefer E.J., Zech L.A., Schwartz D.E., Brewer H.B. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann. Intern. Med. 93:1980;261.
4. Assmann G, von Eckardstein A, Brewer HB. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. 7th ed. New York:McGraw-Hill, 1994. p. 2053.
5. Lux S.E., Levy R.I., Gotto A.M., Fredrickson D.S. Studies on the protein defect in Tangier disease: Isolation and Characterization of an abnormal high density lipoprotein. J. Clin. Invest. 51:1972;2505.
6. Assmann G., Herbert P.N., Fredrickson D.S., Forte T. Isolation and characterization of an abnormal high density lipoprotein in Tangier disease. J. Clin. Invest. 60:1977;242.
7. Serfaty-Lacrosniere C., Civeira F., Lanzberg A., et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 107:1994;85.
8. Schaefer E.J., Blum C.B., Levy R.I., et al. Metabolism of high density lipoprotein apolipoproteins in Tangier disease. N. Eng. J. Med. 299:1978;905.
9. Assmann G., Smootz E. High density lipoprotein infusion and partial plasma exchange in Tangier disease. Eur. J. Clin. Invest. 8:1978;131.
10. Schaefer E.J., Anderson D.W., Zech L.A., et al. Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J. Lipid Res. 22:1981;217.
11. Makrides S.C., Ruiz-Opazo N., Hayden M., et al. Sequence and expression of Tangier apo A-I gene. Eur. Biochem. 173:(2):1988;465.
12. Law S.W., Brewer H.B. Tangier disease: the complete mRNA sequence encoding for preproapo AI. J. Biol. Chem. 260:1985;12810.
13. Civeira F., Genest J.J., Pocovi M., et al. The MspI restriction fragment length polymorphism 3′ to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 92:1992;165-176.
14. Alaupovic P., Schaefer E.J., McConathy W.J., Fesmire J.D., Brewer H.B. Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease). Metabolism. 30:1981;805.
15. Rogler G., Trumbach B., Klima B., Lackner K.J., Schmitz G. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler. Thromb. Vasc. Biol. 15:1995;683.
16. Francis G.A., Knopp R.H., Oram J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J. Clin. Invest. 96:1995;78-87.
17. Bodzioch M., Orso E., Klucken J., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:1999;347-351.
18. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:1999;336-345.
19. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:1999;352-355.
20. Remaley A.T., Rust S., Rosier M., et al. Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc. Nat. Acad. Sci. USA. 96:1999;12685-126890.
21. Lawn R.M., Wade D.P., Garvin, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein mediated lipid removal pathway. J. Clin. Invest. 104:1999;R25-R31.
22. Brousseau M.E., Schaefer E.J., Dupuis J., et al. Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds. J. Lipid Res. 41:2000;433-441.
23. Young S.G., Fielding C.J. The ABCs of cholesterol efflux. Nat. Genet. 22:1999;316-318.
24. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin. Chim. Acta. 166:1987;1-8.
25. 2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin. Chem. 28:1982;1379-1388.
26. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W.F., Schaefer E.J. Reference intervals for plasma apolipoprotein A-I determined with a commercially available immunoturbidometric assay: results from the Framingham Offspring Study. Clin. Chem. 42:(4):1996;507-514.
27. Asztalos B.F., Sloop C.H., Wong L., Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim. Biophys. Acta. 1169:1993;291.
28. Asztalos B.F., Roheim P.S. Presence and formation of 'free apolipoprotein A-I-like' particles in human plasma. Arterioscler. Thromb. Vasc. Biol. 15:1995;1419.
29. Asztalos B.F., Lefevre M., Foster T.A., Tulley R., Windhauser M., Wong L., Roheim P.S. Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations. Arterioscler. Thromb. Vasc. Biol. 17:1997;1885.
30. Assmann G., Smootz E., Adler K., Capurso A., Oette K. The lipoprotein abnormality in Tangier disease. Quantitation of A apoproteins. J. Clin. Invest. 59:1977;565.
31. Bojanovski D., Gregg R.E., Zech L.A., Meng M.S., Bishop C., Ronan R., Brewer H.B. In vivo metabolism of proapolipoprotein A-I in Tangier disease. J. Clin. Invest. 80:1987;1042.
32. Mendez A.J., Oram J.F., Bierman E.L. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J. Biol. Chem. 266:1991;10104.
33. Brousseau ME, Eberhart GP, Dupuis J, Asztalos BF, Goldkamp AL, Schaefer EJ, Freeman MW. Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res 2000;41:1125.
34. Eckardstein A., Huang Y., Wu S., Sarmadi A.S., Schwarz S., Steinmetz A., Assmann G. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler. Thromb. Vasc. Biol. 15:1995;1775-1783.
35. Duverger N., Ghalim N., Ailhaud G., Steinmetz A., Fruchart J.C., Castro G. Characterization of apo A-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler. Thromb. 13:1993;126.
36. Duchateau P., Rader D., Duverger N., et al. Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I:A-II and LpA-IV particles from plasma. Biochim. Biophys. Acta. 1182:1993;30.
37. Assmann G., Simantke O., Schaefer H.E., Smootz E. Characterization of high density lipoproteins in patients heterozygous for Tangier disease. J. Clin. Invest. 60:1977;1025.
38. Castro G., Nihoul L.P., Dengremont C., et al. Cholesterol efflux, LCAT activity, and preβ particle formation by serum from human apolipoproteinA-I and apolipoproteinA-I/apolipoproteinA-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 36:(8):1997;2243-2249.
39. Johnson W.J., Kilsdonk E.P.C., van Tol A., Philips M.C., Rothblat G.H. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LP-AI and LP-AI/AII. J. Lipid. Res. 32:1991;1993-2000.